About Avertix

Mr. Berardo is the Chief Executive Officer and Chairman of the board of directors of Carisk Partners, Inc., a specialty risk transfer and care-coordination company, since October 2016 and as an Operating Partner of MBF Healthcare Partners LP, focused on the healthcare sector, since June 2016.

Previously, Mr. Berardo served as Chief Executive Officer of Brighton Health Plan Services, LLC, a healthcare enablement company, from 2013 to 2015. Brighton Health was the controlling shareholder of MagnaCare and Privia Medical. Mr. Berardo spent 18 years at MagnaCare Holdings, Inc., a provider of health plan services, in various roles of increasing seniority, including as Chief Executive Officer from 2007 to 2016, President from 2005 to 2016 and Vice President of Sales and Marketing from 2003 to 2005. He was a member of the board of MagnaCare from 2007 to 2021 and Privia from 2018 to 2021.

Prior to that, Mr. Berardo served as Senior Vice President of Empire Blue Cross Blue Shield and President for Empire HealthChoice HMO, Inc., a health maintenance organization (HMO), from 1996 to 2000. Earlier in his career, Mr. Berardo held leadership positions at the Mount Sinai Health System. Inc., an integrated healthcare system located in New York, New York, MultiPlan Corporation a leading provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency and fairness to the U.S. healthcare industry and U.S. Healthcare, Inc., one of America’s largest HMOs

Mr. Berardo holds a B.A. in Economics from Rutgers University.

Timothy P. Moran joined Avertix in April 2023 as President and Chief Executive Officer.

Previously, Tim served as Chief Executive Officer of Motus GI(Nasdaq: MOTS), a medical device company providing innovative endoscopic solutions for the diagnosis and management of gastrointestinal conditions, from 2018 to 2023. Earlier in his career, from 2015 to 2018, Tim was President, Americas at ConvaTec Group Plc(LON: CTEC), an international medical products and technologies company.Prior to his employment at ConvaTec, he held various leadership roles over the course of eighteen years at Covidien plc(“ Covidien”), an Irish headquartered global health care products company. Following the acquisition of Covidien by Medtronic (NYSE:MDT), Tim was named Global Vice President and General Manager of Patient Care and Safety, a division generating annual revenues exceeding $1B.

In his capacity as CEO, Tim serves on the Board of Avertix. He is also an Independent Director and Chairman of the Board at Motus GI. Tim earned a B.A. in Organizational Communication from The State University of New York at Geneseo.

Philip L. Tom joined Avertix in April 2023 as EVP and Chief Financial Officer.

Philip has over a decade of experience in finance as an investor, advisor, and operator. Most recently, Philip was Principal at Explorer Acquisitions, a serial SPAC sponsor with 7 SPAC IPOs. He’s also served as CFO for Hudson MX, an ad-tech, cloud-based SaaS media solution for commercial advertising, and sat on the investment team at Insight Partners, the global private equity firm based in New York.

He holds a B.A. from Stanford University and started his career in investment banking at Credit Suisse in New York.

David has over 20 years of experience in the development and deployment of complex active cardiovascular implants. He was actively involved in the development of the Avertix Guardian™ system from the start and participated in the first-in-human implant in Brazil, and the first implants in the US and Germany.

Dave took over responsibility for the ALERTS Clinical Study in 2012 and then oversaw the analysis and reporting of efficacy and safety results for the PMA submission, including the amendment that led to FDA approval. Dave has a dozen patents related to medical devices and computer networking technologies.

Prior to Avertix, Dave was a Director at Corente, Inc. (formally OpenReach), a leader in managed secure networks. At OpenReach, Dave managed the provisioning and support of networks in 40 countries. Before joining Corente, Dave spent 15 years at AT&T Bell Laboratories. During that time, Dave worked within the R&D team that created Ethernet over twisted pair wire. Dave traveled to over 44 countries during this period to support and troubleshoot network problems for AT&T and NCR. Prior to AT&T, Dave worked in R&D for Perkin Elmer Corporation on some of the world’s first 32-bit minicomputers, used to power state of the art military simulators. Dave’s first job after graduating from The Catholic University of America was in the Inhalation Toxicology Labs of Hazleton Laboratories in Reston, Virginia. This lab was the setting for the best seller “The Hot Zone” which chronicled the early discoveries associated with the ebola virus.

Bryan Finley joined Avertix in May 2023. In his current role as Senior Vice President of Global Sales, Bryan oversees all commercial sales activities for the GUARDIAN System.

Over the past 30 years, Bryan has built high performance sales teams within the Interventional Cardiology space. Prior to joining Avertix he held key sales leadership positions at medical technology firms Abiomed (acquired by Johnson & Johnson) and Shockwave Medical.

Earlier in his career with the USCI Division of CR Bard, Bryan held a variety of ascending sales, sales training, field management and corporate marketing roles, and played a direct role in the evolution of angioplasty.

Living his mission to put patients first, Bryan is committed to bringing the groundbreaking GUARDIAN heart attack detection and warning technology to the tens of thousands of heart attack survivors who would benefit from the protection and peace-of-mind that GUARDIAN delivers.

Bryan is a graduate of The College Of New Jersey, holding a Bachelor of Science degree in Criminal Law and Justice with a minor in Psychology.

Gregg Turi has more than 30 years of successful healthcare technology product design, development, and manufacturing transfer efforts. His background in product development includes extensive knowledge and experience with FDA and ISO related design controls.

Prior to joining Avertix, he founded and led Chameleon Design Solutions, which was preceded by an 18-year tenure at Hi-tronics Designs, Inc., a subsidiary of St. Jude Medical. He holds 18 patents all around implantable medical devices.

He has been involved with the design and development of all Avertix’s IMD and EXD products, from the initial animal studies through ALERTS trial, commercialization of the FDA approved Guardian System, and into development of its next-generation product.

Gregg received his Bachelor of Science in Electrical Engineering from NJ Institute of Technology.